How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about zanubrutinib

Marketing authorisation indication

2.1 Zanubrutinib (Brukinsa, BeiGene) is indicated for 'the treatment of adult patients with chronic lymphocytic leukaemia'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for zanubrutinib.

Price

2.3 A 120‑pack of 80‑mg zanubrutinib capsules costs £4,928.65 (excluding VAT; BNF online accessed July 2023). The company has a commercial arrangement (simple discount patient access scheme). This makes zanubrutinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.